Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate
cancer cells and either kill them or deliver cancer-killing substances to them without
harming normal cells. Combining more than one drug or combining monoclonal antibody with
chemotherapy may kill more cancer cells. It is not yet known which treatment regimen is more
effective for acute myelogenous leukemia.
PURPOSE: Randomized phase II trial to compare the effectiveness of three treatment regimens
in treating patients who have relapsed or refractory acute myelogenous leukemia.